Denali Therapeutics Inc.
DNLI
$19.00
$1.166.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -126.90M | -124.12M | -132.97M | -114.75M | -107.19M |
| Total Depreciation and Amortization | 3.86M | 3.96M | 3.21M | -5.28M | 2.27M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 21.97M | 21.58M | 20.22M | 25.76M | 15.43M |
| Change in Net Operating Assets | -6.22M | 23.29M | -21.93M | 10.56M | 30.35M |
| Cash from Operations | -107.30M | -75.30M | -131.47M | -83.72M | -59.14M |
| Capital Expenditure | 1.38M | -4.28M | -5.08M | -5.09M | -3.88M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 56.45M | 162.21M | 23.83M | 177.30M | 97.54M |
| Cash from Investing | 57.83M | 157.94M | 18.75M | 172.21M | 93.66M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.36M | -2.43M | -4.36M | -8.32M | -24.02M |
| Issuance of Common Stock | 583.00K | 4.06M | 595.00K | 4.16M | 5.46M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | 0.00 |
| Cash from Financing | -778.00K | 1.62M | -3.76M | -4.17M | -18.56M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -50.24M | 84.26M | -116.48M | 84.32M | 15.96M |